Non-hallucinogenic neuroplastogens offer benefits over classical psychedelics, including simpler delivery, stronger IP protection, and patient tolerability, writes Enveric Biosciences CEO Joseph ...

As new therapies for obesity enter the market, biopharmaceutical companies will need to tune commercial strategies to win ...

On this weeks Business of Biotech episode, Ebrahim Delpassand, M.D., founder, CEO, and chairman of the board at RadioMedix talks about his personal journey standing up and growing a ...

Catalyst Flex, a functional service provider (FSP) solution of Catalyst Clinical Research, is a multi-therapeutic niche contract research organization (CRO)with flexible, fit-for-purpose offerings in ...

On this weeks Business Of Biotech episode, Oury Chetboun, co-founder and CEO of Seekyo, a French biotech, talks about the range of experiences that prepared him to lead a company focused on developing ...

Executive coach Joel Garfinkle shares tips to help "quiet" life science leaders assert themselves and move from invisible to ...

This Patient Experience Optimization (PXO) model bridges the critical gap where most clinical trial patients drop out before reaching consent.

For clinical operations leaders facing tighter budgets and higher expectations, patient experience optimization is essential for building trials that patients can successfully navigate.

Lumen Bioscience is putting the farm in biopharma — literally! In this episode of Better Biopharma, Lumens EVP of production and development, Craig Behnke, Ph.D., explains the companys ...

Twenty years ago, Roger Cone, Ph.D. made a key discovery in obesity science which could help Courage Therapeutics deliver products that improve upon currently available treatments for obesity.

Life sciences companies can look to the automotive industry for ideas about collaborating with patients to co-create new products, write Noël Theodosiou and Patrick O. Gee.

By sharing early-stage tools and data openly, life sciences companies can minimize duplication and de-risk R&D without risking exclusive rights over valuable assets, writes Richard Gold.